NOVATEC LIGHTBLADE LASER ENTERING CLINICAL TRIAL FOR PARK
This article was originally published in The Gray Sheet
Executive Summary
NOVATEC LIGHTBLADE LASER ENTERING CLINICAL TRIAL FOR PARK in the next few weeks, the company says. Novatec Laser Systems was granted an investigational device exemption to start treating patients suffering low to moderate myopia using the solid-state surface laser. The study will involve five to ten patients at the Manhattan Eye, Ear and Throat Hospital in New York City and should be completed in three to six months, according to the company.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.